Skip to content

Study · Randomized controlled trial · n = 102 · 2021

3 results

Effect of Liraglutide on Arterial Inflammation Assessed as [18F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.

Ripa RS, Zobel EH, von Scholten BJ, Jensen JK, Binderup T, Diaz LJ, Curovic VR, Hansen TW, Rossing P, Kjaer A

Circulation. Cardiovascular imaging30 Jun 2021Cited by 48 (Europe PMC)

PMID34187185 (opens in a new tab)PMCIDPMC8300846 (opens in a new tab)DOI10.1161/circimaging.120.012174 (opens in a new tab)PepBankPUB-34187185
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, 26 weeks of liraglutide did not change arterial inflammation on FDG PET/CT more than placebo (mean difference 0.05, P=0.53).

    In plain wordsIn adults with type 2 diabetes, liraglutide did not reduce inflammation in artery walls more than placebo over 26 weeks.

    Peptide
    Liraglutide
    Outcome
    No significant changeChange in vascular inflammation (FDG active-segment TBR)
    Study

    n = 102

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    up to 1.8 mg · 26 weeksAs given in this study (human).

    Measurements

    mean difference in TBR change
    0.05 ratio
    liraglutide vs placebo

    Source sentences

    Summary
    change from baseline to 26 weeks was -0.04 (95% CI, -0.17 to 0.08) in the liraglutide group compared with -0.09 (-0.19 to 0.01) in the placebo group (mean difference, 0.05 [95% CI, -0.11 to 0.21], P=0.53)
    2 context sentences
    Summary · context
    Patients with type 2 diabetes were via computer-generated randomization list assigned (1:1) liraglutide up to 1.8 mg or placebo once daily for 26 weeks.
    Summary · context
    Between October 26, 2017, and August 16, 2019, 147 patients were screened and 102 were randomly assigned to liraglutide (n=51) or placebo (n=51) and 99 (97%) completed the trial.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, secondary analyses of carotid FDG uptake and other atherosclerosis indices confirmed no effect of liraglutide on the primary result.

    In plain wordsIn adults with type 2 diabetes, other measures of artery disease also showed no benefit of liraglutide over placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeCarotid FDG uptake and other indices of atherosclerosis
    Study

    n = 102

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    up to 1.8 mg · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Secondary analyses restricted to [18F]-fluorodeoxyglucose positron emission tomography of the carotid arteries as well as other indices of atherosclerosis confirmed the primary result.
    2 context sentences
    Summary · context
    Patients with type 2 diabetes were via computer-generated randomization list assigned (1:1) liraglutide up to 1.8 mg or placebo once daily for 26 weeks.
    Summary · context
    Between October 26, 2017, and August 16, 2019, 147 patients were screened and 102 were randomly assigned to liraglutide (n=51) or placebo (n=51) and 99 (97%) completed the trial.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In an explorative analysis, the effect of liraglutide on vascular inflammation possibly differed by history of cardiovascular disease (interaction P=0.052).

    In plain wordsAn exploratory check hinted that liraglutide might work differently in people with past heart or vessel disease, but this was not clear-cut.

    Peptide
    Liraglutide
    Outcome
    MixedInteraction of treatment with history of cardiovascular disease
    Study

    n = 102

    Comparator
    Placebo
    Analysis
    Exploratory
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    up to 1.8 mg · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    We performed an explorative analysis of interaction between treatment group and history of cardiovascular disease (P=0.052).
    3 context sentences
    Summary · context
    An explorative analysis indicated a possible effect in persons with history of cardiovascular disease, in line with current guidelines where liraglutide is recommended to patients with history of cardiovascular disease.
    Summary · context
    Patients with type 2 diabetes were via computer-generated randomization list assigned (1:1) liraglutide up to 1.8 mg or placebo once daily for 26 weeks.
    Summary · context
    Between October 26, 2017, and August 16, 2019, 147 patients were screened and 102 were randomly assigned to liraglutide (n=51) or placebo (n=51) and 99 (97%) completed the trial.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT03449654

Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes

Steno Diabetes Center Copenhagenn = 10226 Oct 2017 to 16 Aug 2019

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 11 Jun 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.